Tyra Biosciences (TYRA) Shares Slide After Phase 2 Data, Is The Pullback A Valuation Opportunity?

Tyra Biosciences stock reacts to SURF302 Phase 2 data

Tyra Biosciences (TYRA) drew fresh attention after releasing initial Phase 2 SURF302 data for oral dabogratinib in FGFR3 altered low grade intermediate risk non muscle invasive bladder cancer on 9 September 2026.

The update provided clinical proof of concept for selective oral FGFR3 inhibition, highlighted a 60 mg once daily dose as a potential adjuvant option, and outlined plans to discuss Phase 3 design with regulators.

Tyra Biosciences has just paired this Phase 2 readout with a busy news run that included a dedicated results call on 4 September and a presentation at the Cantor healthcare conference on 9 September. Yet the share price has retreated, with the 1-day move down 6.41% and the 7-day share price return down 23.11%, even as the 1-year total shareholder return sits at 78.96%. This suggests long term holders are still well ahead despite fading near term momentum.

Scan 15 high quality undiscovered gems that, like Tyra Biosciences after its SURF302 update, pair active clinical programs with under-the-radar market attention.

Tyra Biosciences now trades well below recent highs, even as fresh SURF302 data and a busy clinical pipeline sit in plain view. Is this pullback a read on fundamentals, or just sentiment resetting before valuation catches up?

Preferred Price-to-Book of 3.7x: Is it justified?

Valuation on Tyra Biosciences today hinges less on earnings and more on what investors are willing to pay for its asset base, with the stock closing at $22.03 and trading on a 3.7x price-to-book ratio while the latest SURF302 data sits under fresh scrutiny.

The P/B multiple compares Tyra Biosciences' market value to its net assets on the balance sheet and is often used for early stage or loss making biotechs where revenue is minimal and net income remains negative. With the business reporting $0 in revenue and a loss of $148.565 million, this kind of asset based yardstick becomes a shorthand for how much of the pipeline and platform investors are baking into the share price.

Relative to peers, that 3.7x figure cuts both ways. It screens as good value against the 5.8x peer average cited in the checks, which suggests the market is pricing Tyra Biosciences at a lower premium to book than many similar sized comparables. Against the broader US biotechs industry though, where the average P/B is 2.3x, the stock carries a much richer tag and the sector level comparison points to investors paying up materially more than the typical biotech listing for each dollar of net assets.

Put together, the preferred multiple signals a mixed picture, with Tyra Biosciences looking relatively cheap versus a tighter peer set but clearly expensive against the wider industry and with no fair ratio guide available to indicate where that P/B could settle over time.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 3.7x (ABOUT RIGHT)

Still, Tyra Biosciences faces clear pressure if future SURF302 updates disappoint or if ongoing losses of $148.565 million weigh more heavily on sentiment.

Find out about the key risks to this Tyra Biosciences narrative.

Next Steps

If this read on Tyra Biosciences feels mixed, treat it as a prompt to inspect the figures yourself and move quickly while sentiment is unsettled. To round out your view, take a close look at the 4 important warning signs.

Looking for more investment ideas beyond Tyra Biosciences?

If Tyra Biosciences has sharpened your focus on selective opportunities, do not stop here. Broader idea hunting with structured tools can help you act before the crowd.

• Target stability by scanning a focused 11 resilient stocks with low risk scores that filters for companies with resilience built into their risk scores.
• Hunt for potential bargains through a curated 32 high quality undervalued stocks that highlights quality businesses priced below what their fundamentals might suggest.
• Zero in on financial strength with a list of solid balance sheet and fundamentals (23 results) that spotlights businesses carrying robust balance sheets and healthier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com